Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Reuters NewMedia - Friday September 18, 1998
Some of the roughly 60,000 HIV-infected patients who had been taking Norvir capsules are switching to liquid Norvir, which is in plentiful supply, said Melissa Brotz, spokeswoman for the North Chicago, Ill.-based drug company. Supplies of Norvir capsules on hand at Abbott warehouses were depleted three weeks ago, while external inventories will be exhausted "within the next month or so," Brotz said.
"We don't have news on the capsule manufacturing...We have not yet found the exact source of the original problem," Brotz said. "We're hopeful that we will resume capsule production soon. But at this time we don't have a date."
On July 27, Abbott announced it was having difficulties making Norvir capsules involving formation of an undesired crystalline structure that changes how the capsules dissolve.
Norvir is one of four major protease inhibitors taken to fight HIV, usually combined with other drugs, such as AZT.
Pharmacists, physicians and patients are getting guidance from Abbott to help manage the switch from capsule to liquid.
Norvir, with $170 million in sales last year, ranks fourth in the roughly $2.2 billion world protease inhibitor market. The drug had been expected to produce revenues of about $250 million this year for Abbott, analysts said.
The three top-selling protease inhibitors are Merck & Co. Inc.'s (NYSE:MRK - news) Crixivan at $750 million in estimated 1998 sales, Agouron Pharmaceuticals Inc.'s (Nasdaq:AGPH - news) Viracept at $750 million, and Roche Holding Ltd.'s Invirase at $400 million, drug industry analysts said.
Shares in Abbott were up 50 cents at $43.06 in midday trading on Friday.
980918
RE980912
Copyright © 1998 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .